TP53 and central nervous system cancer: Treatment of glioma or glioblastoma-initiating cells in vitro or of orthotopic brain tumors with KU-60019 up to 1 h before irradiation resulted in increased radiosensitization and doubled survival time of the mice, respectively, especially if the glioma cells were mutants for p53 [74,75].